Chemical Information
Antiviral agent ID	DrugRepV_6126
Antiviral agent name	Tomatidine
IUPAC Name	(1R,2S,4S,5'S,6S,7S,8R,9S,12S,13S,16S,18S)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-piperidine]-16-ol
SMILES (canonical)	CC1CCC2(C(C3C(O2)CC4C3(CCC5C4CCC6C5(CCC(C6)O)C)C)C)NC1
SMILES (isomeric)	C[C@H]1CC[C@]2([C@H]([C@H]3[C@@H](O2)C[C@@H]4[C@@]3(CC[C@H]5[C@H]4CC[C@@H]6[C@@]5(CC[C@@H](C6)O)C)C)C)NC1
Molecular Formula	C27H45NO2
Molecular Weight (g/mol)	415.662
InChl	InChI=1S/C27H45NO2/c1-16-7-12-27(28-15-16)17(2)24-23(30-27)14-22-20-6-5-18-13-19(29)8-10-25(18,3)21(20)9-11-26(22,24)4/h16-24,28-29H,5-15H2,1-4H3/t16-,17-,18-,19-,20+,21-,22-,23-,24-,25-,26-,27-/m0/s1
Synonyms	Tomatidin | (3beta,5alpha,22beta,25S)-Spirosolan-3-ol | 5alpha-Tomatidan-3beta-ol | (22S,25S)-5alpha-spirosolan-3beta-ol
Structural Information
Clinical Information
Biological Information
Secondary Indication	Dengue virus (DENV) 3 H87
Secondary Indication (Approaches)	Experimental
Secondary Indication (Methods)	In-vitro
Secondary Indication (Model system) [cell lines/ animal models]	Huh-7
Secondary Indication (Viral titer)	1 MOI
Secondary Indication (Drug concentration)	4.87 μM
Secondary Indication (Cell based assay)	MTT assay
Secondary Indication (Change)	Decrease
Secondary Indication (Type of Inhibition)	EC50 [ 50 % ]
Reference	Diosa-Toro M, Troost B, van de Pol D, Heberle AM, Urcuqui-Inchima S, Thedieck K, Smit JM..Tomatidine, a novel antiviral compound towards dengue virus..Antiviral Res. 2019 Jan;161:90-99. doi: 10.1016/j.antiviral.2018.11.011. Epub 2018 Nov 22. PMID:30468746
Comment	Time-of-drug-addition experiments revealed that tomatidine inhibits virus particle production when added pre, during and up to 12 h post-infection. Subsequent experiments show that tomatidine predominantly acts at a step after virus-cell binding and membrane fusion but prior to the secretion of progeny virions.